A NOVEL FORMULATION DESIGN FOR EXTENDED RELEASE TABLET OF ETODOLAC FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
DOI:
https://doi.org/10.47750/pnr.2022.13.S01.116Keywords:
Etodolac, Extended Release, HPMC, MCC, Direct CompressionAbstract
This study was aimed formulate of an extended-release tablet of Etodolac for the disease Rheumatoid arthritis were prepared by using
different excipient like HPMC, Carbapol, Magnesium Stearate, MCC, at different concentrations. The wavelength of Etodolac 277nm. In
precompression Study Powdered drug were evaluated for Angle of repose (36.42º- 42.01º), Bulk Density (0.19 - 0.25) g/mL and Tapped
density (0.23-0.29) g/mL and compressibility index (13.79- 27.58). The results obtained were found to be satisfactory and within the
specified limits. After compression parameters like Thickness, Hardness, Weight variation, Friability and In Vitro drug release studies were
evaluated. In the present study the effect of types and concentration of polymer were studied on In-Vitro drug release. It shows that increase
in concentration of polymer results in the extended drug release for 24 hours. In present studies, formulation containing Carbapol is probably
showing release up to 94.55% drug release within 24hrs